DUN'S 100 - 2016

550 / 730

Medical Equipment /
Cosmetics
550
2016 | DUN’S 100 DUN’S 100 | 2016
DUN’S 100 | 2016 2016 | DUN’S 100
Industrial Companies 1 1 Pharmaceuticals & Cosmetics
RANK
Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. is a
leading global pharmaceutical company,
committed to increasing the availability of
high-quality healthcare by developing, producing
andmarketing accessible genericmedicines and a
focused portfolio of specialty medicines.
Teva is the world’s largest maker of generic medi-
cines, with a global portfolio of more than 1,000
molecules in 35,000 formulations sold in about
100 countries.
Teva is a world leader in innovative specialty phar-
maceuticals, known for its prominent portfolios in
Central Nervous System (CNS), including multiple
sclerosis, pain, migraine, movement disorders and
neurodegenerative diseases, and in respiratory,
as well as for its strong commercial presence in
oncology and women’s health.
Generic Drugs
Teva is a global power in generic drugs and touches
the lives of 200 million people around the world
every day. Teva holds one of the most extensive
portfolios of drugs in the pharmaceutical industry
and has an unparalleled impact on health services
around the world. The Company helpsmeet critical
consumer and social needs through themost com-
prehensive product range in the industry. Teva is
the largest generic pharmaceutical company in the
US and the European Union and enjoys a leading
position in most European countries.
Innovative and Specialty Drugs
Teva has a focused portfolio of innovative drugs
built around its core therapeutic areas.
Central Nervous System (CNS), pain, migraine
and movement disorders: Teva’s CNS portfolio
of innovative medicines including Copaxone®,
the leading brand for the treatment of relapsing-
remitting multiple sclerosis, which exists in two
doses: 20mg for daily use, and 40mg for three
times a week use; and Azilect®, for the treatment
of Parkinson’s disease. The Company continues to
invest in the development of opioid alternatives
and opioid substances that deter addiction to pain
treatments, and is developing TEV-48125, an ex-
perimental drug, which has successfully completed
Phase 2 clinical trials, and which is aimed to treat
chronic and episodic migraines. The company is
also developingSD-809 for the treatment of chorea
associated with Huntington’s disease, tardive dys-
kinesia, and Tourette syndrome.
Respiratory Products: Teva has a leading market
presence in respiratory products through a variety
of drugs for asthma, chronic obstructive pulmo-
nary disease (COPD) and allergic rhinitis. Its varied
product range is concentrated on the optimization
of respiratory treatments using innovative delivery
systems and treatments to address unmet needs.
Among Teva’s respiratory products: ProAir® Re-
spiClick for the treatment of asthma and COPD;
QVAR®, for the treatment of asthma; and QNASL®
Nasal Aerosol, for the treatment of seasonal and
annual allergic rhinitis.
Women’s Health Products: Teva develops and
markets a wide range of products that promote
women’s health. Among its major products: Plan
B One-Step®, an emergency contraceptive pill;
Quartette™, birth control pills to be taken in se-
quence; and Seasonique®, birth control pills for
between periods.
Oncology Products: Teva’s oncology drugs are
dedicated to improving the lives of cancer pa-
tients. Among its oncology drugs: Treanda® and
Bendeka® for chronic lymphocytic leukemia and
slownon-Hodgkin B-cell lymphoma; andSynribo®
for the treatment of adults in the chronic phase or
accelerated phase of chronicmyeloid leukemia. In
addition, Teva markets some biological drugs that
are often part of drug regimen of oncology patients,
such as Granix®, which is G-CSF short-term; and
Lonquex®, an innovate long-term G-CSF, for the
treatment of neutropenia.
OTC - Over the Counter Drugs
Teva’s global OTCbusiness is expanding, especially
thanks to its winning partnership with Procter &
Gamble (P&G), which combines the production
capacities andmarket access of Teva with themar-
keting expertise of P &G and its extensive global
platform.
Active Pharmaceutical Ingredients
Teva is one of the world’s leading manufacturers
of active pharmaceutical ingredients; the essen-
tial raw materials for the pharmaceutical industry.
Financial Information
In 2015, Teva reported net revenue of $ 19.7 billion
while diluted earnings per share on a non-GAAP
basis totaled $5.46. Revenue in the US totaled $
11.2 billion; revenue in Europe totaled $ 4.8 bil-
lion while revenue in the rest of the world totaled
$ 3.1 billion.
Other Important Developments at Teva
• Actavis Generics: In July 2015 the company an-
nounced the acquisition of Allergan Generics for
$40.5 billion in cash and shares, creating a trans-
formative generics and specialty company well po-
sitioned towin in global healthcare. The acquisition
strongly reinforces Teva’s strategy, accelerates the
creation of its new business model and opens a
new set of possibilities for the company in gener-
ics and specialty
• Rimsa: InMarch 2016, Teva completed the acqui-
sition of Rimsa, a leading pharmaceutical manu-
facturing and distribution company inMexico. With
the completion of the acquisition, Teva is now one
of the leading pharmaceutical companies inMexi-
co, the second largest market in Latin America and
one of the top five emerging markets globally.
• Takeda Business Venture: In April 2016 Teva
formed a business venture with Takeda, Japan’s
largest pharmaceutical company, presenting a
new, collaborative business model in line with
government objectives and ultimately serving
millions of patients
• AuspexPharmaceuticals: InMay 2015, Teva com-
pleted the acquisition of Auspex in a deal expected
to strengthen its core central nervous system fran-
chise withSD-809 (deutetrabenazine), developed
to treat several movement disorders.
• Labrys Biologics: In July 2014, Teva acquired
Labrys Biologics, including itsmain asset, LBR-101
(now TEV-48125), a monoclonal antibody, which
is in Phase 3 clinical trials to prevent episodic or
chronic migraines.
Market Information
Teva’s shares are traded on the New York Stock
Exchange (NYSE) under the “TEVA” symbol, and
on the Tel Aviv Stock Exchange.
l e a d i n g e x ecu t i v es
Iris Beck-Codner Group EVP, Corporate Marketing and
Communications
Eyal Desheh Group EVP, CFO
Richard S. Egosi Group EVP, Chief Legal Officer, Corporate
Secretary
Dr. Michael Hayden President of Global Research and
Development, and Chief Scientist
Dr. Robert Koremans President and CEO, Global Specialty
Medicines group
Dr. Carlo de Notaristefani President, and CEO, Global
Operations
Sigurdur (Siggi) Olafsson President and CEO, Global
Generic Medicines Group
Mark Sabag Group EVP, Global Human Resources Officer
Timothy R. Wright Executive Vice President, Head of Business
Development, Strategy and Innovation
5 Basel St., P.O.B. 3190, Petach Tikva 49131
Tel: 972-3-9267267
Fax:972-3-9234050
Erez Vigodman
President and CEO
Prof. Yitzhak
Peterburg
Chairman